Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy

Grinspoon, 2005, Cardiovascular risk and body-fat abnormalities in HIV-infected adults, N Engl J Med, 352, 48, 10.1056/NEJMra041811 Riddler, 2003, Impact of HIV infection and HAART on serum lipids in men, JAMA, 289, 2978, 10.1001/jama.289.22.2978 Friis-Moller, 2003, Combination antiretroviral therapy and the risk of myocardial infarction, N Engl J Med, 349, 1993, 10.1056/NEJMoa030218 DAD Study Group, 2007, Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, 356, 1723, 10.1056/NEJMoa062744 El-Sadr, 2006, CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, 355, 2283, 10.1056/NEJMoa062360 Cespedes, 2005, Cardiovascular and endothelial disease in HIV infection, Curr Infect Dis Rep, 7, 309, 10.1007/s11908-005-0064-3 Lichtenstein K, Armon C, Buchacz K. Analysis of cardiovascular risk factors in the HIV outpatient study (HOPS) cohort. Presented at the Thirteenth Conference on Retroviruses and Opportunistic Infections (CROI); February 5–8, 2006, Denver, Colorado. National Cholesterol Education Program N Dube, 2003, Clin Infect Dis, 37, 613, 10.1086/378131 Lundgren, 2008, European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV, HIV Med, 9, 72, 10.1111/j.1468-1293.2007.00534.x Law, 2006, The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study, HIV Med, 7, 218, 10.1111/j.1468-1293.2006.00362.x Fichtenbaum, 2002, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047, AIDS, 16, 569, 10.1097/00002030-200203080-00008 Aboulafia, 2000, Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease, AIDS Patient Care STDS, 14, 13, 10.1089/108729100318091 Carr R, Andre A, Bertz R. Concomitant administration of ABT-378/ritonavir (ABT-378/r). Results in a clinically important pharmacokinetic (PK) interaction with atorvastatin but not pravastatin [abstract 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 17–20, 2000. Aberg, 2006, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG study A5108, AIDS, 20, 725, 10.1097/01.aids.0000216373.53819.92 Raritan, 2008, Prezista (Darunavir) package insert, Tibotec Therapuetics van der Lee, 2007, Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients, Antivir Ther, 12, 1127, 10.1177/135965350701200711 Kiser, 2008, Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers, J Acquir Immune Defic Syndr, 47, 570, 10.1097/QAI.0b013e318160a542 Gerber, 2005, The effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of ACTG 5108 study, J Acquir Immune Defic Syndr, 39, 307, 10.1097/01.qai.0000167156.44980.33 Croxtall, 2008, Raltegravir, Drugs, 68, 131, 10.2165/00003495-200868010-00009 Kiser, 2008, Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV, Curr Opin HIV AIDS, 3, 330, 10.1097/COH.0b013e3282fbaa6b Moyle, 2005, Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy, AIDS, 15, 1503, 10.1097/00002030-200108170-00007 Calza, 2003, Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART, AIDS, 17, 851, 10.1097/00002030-200304110-00010 Aberg, 2005, A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087, AIDS Res Hum Retroviruses, 21, 757, 10.1089/aid.2005.21.757 Aslangul E, Assoumou L, Bittar R, et al. ANRS 126, a prospective, randomized, open label trial comparing the efficacy and safety of rosuvastatin versus pravastatin in HIV-infected subjects receiving ritonavir boosted PI with lipid abnormalities [abstract LBPS7/2]. Eleventh European AIDS Conference. Madrid, October 24–27, 2007. Kastelein, 2008, Simvastatin with or without ezetimibe in familial hypercholesterolemia, N Engl J Med, 358, 1431, 10.1056/NEJMoa0800742 Negredo, 2006, Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins, AIDS, 20, 2159, 10.1097/01.aids.0000247573.95880.db Bennett, 2007, Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV, Lipids Health Dis, 6, 15, 10.1186/1476-511X-6-15 Wohl D, Hsue P, Richard S, et al. Ezetimibe' effects on the LDL cholesterol levels of HIV-infected patients receiving HAART [abstract 39]. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 25–28, 2007. Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density cholesterol level: a meta-analysis of population-based prospective studies, J Cardiovasc Risk, 3, 213, 10.1097/00043798-199604000-00014 Cullen, 2000, Evidence that triglycerides are an independent coronary artery disease risk factor, Am J Cardiol, 86, 943, 10.1016/S0002-9149(00)01127-9 McBride, 2007, Triglycerides and risk factors for coronary heart disease: editorial, JAMA, 298, 236, 10.1001/jama.298.3.336 Miller, 2002, A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia, AIDS, 16, 2195, 10.1097/00002030-200211080-00012 Thomas, 2000, Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities, Pharmacotherapy, 20, 727, 10.1592/phco.20.7.727.35179 de Luis, 2001, Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor, Nutrition, 17, 414, 10.1016/S0899-9007(01)00582-2 Calza, 2002, Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART, Infection, 30, 26, 10.1007/s15010-001-2052-3 Caramelli, 2001, Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate, Braz J Infect Dis, 5, 332, 10.1590/S1413-86702001000600007 Palacios, 2002, Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy, J Acquir Immune Defic Syndr, 31, 251, 10.1097/00126334-200210010-00018 Badiou, 2004, Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults, Atherosclerosis, 172, 273, 10.1016/j.atherosclerosis.2003.10.006 Rao, 2004, Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy, Am J Med Sci, 327, 315, 10.1097/00000441-200406000-00003 Kris-Etherton, 2003, Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association, Arterioscler Thromb Vasc Biol, 23, 151, 10.1161/01.ATV.0000057393.97337.AE De Truchis, 2007, Reduction in triglyceride levels with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study, J Acquir Immune Defic Syndr, 44, 278, 10.1097/QAI.0b013e31802c2f3d Wohl, 2005, Randomized study of the safety and efficacy of fish oil (omega-3 fatty acids) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia, Clin Infect Dis, 41, 1498, 10.1086/497273 Gerber, 2008, Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186, J Acquir Immune Defic Syndr, 47, 459, 10.1097/QAI.0b013e31815bace2 Baril, 2007, Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia, HIV Clin Trials, 8, 400, 10.1310/hct0806-400 Gerber, 2004, Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy, Clin Infect Dis, 39, 419, 10.1086/422144 Dubé, 2006, Safety and efficacy of extended-release niacin for the treatment of dyslipidemia in patients with HIV infection: AIDS Clinical Trials Group study A5148, Antivir Ther, 11, 1081, 10.1177/135965350601100802 Lichtenstein K, Armon C, Buchacz K, et al. Analysis of cardiovascular risk factors in the HIV outpatient study cohort [abstract 735]. In: Program and abstracts of the 13th conference on retroviruses and opportunistic infections. 2006; Denver, February 5–8, 2006. Barragan, 2006, Switching strategies to improve lipid profile and morphologic changes, AIDS Rev, 8, 191 D:A:D Study Group, 2008, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Lancet, 371, 1417, 10.1016/S0140-6736(08)60423-7 Jones, 2005, Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens, J Acquir Immune Defic Syndr, 40, 565, 10.1097/01.qai.0000187443.30838.3e Tarr, 2005, Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy–associated lipid disorders, J Infect Dis, 191, 1419, 10.1086/429295 Foulkes, 2006, Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy, PLoS Med, 3, e52, 10.1371/journal.pmed.0030052 Kumar, 2006, A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity, HIV Med, 7, 85, 10.1111/j.1468-1293.2006.00346.x Gallant, 2004, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial, JAMA, 292, 191, 10.1001/jama.292.2.191 Squires, 2003, Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial, Ann Intern Med, 139, 313, 10.7326/0003-4819-139-5_Part_1-200309020-00006 Madruga, 2007, The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy, HIV Clin Trials, 8, 381, 10.1310/hct0806-381 Guillemi S, Toulson A, Joy R. Changes in lipid profile upon switching from lopinavir/ritonavir (LPV/r) to atazanavir + ritonavir (ATZ + RTV) based HAART. Paper presented at the XVI International AIDS Conference. Toronto, August 13–18, 2006. Gatell, 2007, Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results, Clin Infect Dis, 44, 1484, 10.1086/517497 Martinez E, Azuaje C, Antela A. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia [abstract # 850]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, February 22–25, 2005. Calza, 2005, Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia, AIDS, 19, 1051, 10.1097/01.aids.0000174451.78497.8f Van Der Valk M, Friis-Møller N, Sabin C. Effect of interventions to improve dyslipidaemia. Paper presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom, November 12–16, 2006.